| Browse All

Vericel Corporation (VCEL)

Healthcare | Biotechnology | Cambridge, United States | NasdaqGM
35.68 USD +1.91 (5.656%) ⇧ (April 17, 2026, 4 p.m. EDT)
After hours: 35.68

Short-term: ★★☆☆☆ | Long-term: ★★★★☆ | Dividends: ☆☆☆☆☆
Hot Take | April 18, 2026, 11:38 p.m. EDT

Despite strong 'Strong Buy' analyst ratings and recent FDA wins, VCEL faces a 2-week bearish technical trap. The specific options flow targeting a 20+% drop below the $30 zone clashes with the short-term forecast of a -2.3% move, creating a high-risk environment for momentum buyers while the stock trades at a premium Valuation (Forward P/E ~44) relative to its muted revenue growth.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
MSTL ✓0.065362
AutoTheta0.070775
AutoETS0.071767
AutoARIMA0.078248

Forecast horizon: 45 days | Selected: MSTL

Forecast Reliability
Score 45%
H-stat 7.34
Ljung-Box p 0.000
Jarque-Bera p 0.475
Excess Kurtosis -0.89
Attribute Value
Sector Healthcare
Debt to Equity Ratio 27.321
Revenue per Share 5.488
Market Cap 1,817,239,552
Trailing P/E 111.50
Forward P/E 44.32
Beta 1.21
Profit Margins 5.98%
Website https://www.vcel.com

As of April 18, 2026, 11:38 p.m. EDT: Options flow shows a bearish short-term outlook with massive put buying concentrated in the money on the near-dated expirations. Specifically, on April 17th, 'New Flow' indicates aggressive volume (2.9k) at the 25.0 put strike, which is significantly below the current price of ~$35.68, suggesting a hedge or shorting strategy targeting a significant drop. Conversely, call volume is sparse, with the 45.0 strike showing high implied volatility (3.88) relative to others, yet not balanced by corresponding volume oleverage, indicating skepticism about immediate upside. The IV skew is heavily skewed against the upside for short-term traders.


Info Dump

Attribute Value
52 Week Change -0.126988
Address1 64 Sidney Street
All Time High 1,590.0
All Time Low 1.69
Ask 35.8
Ask Size 2
Audit Risk 4
Average Analyst Rating 1.3 - Strong Buy
Average Daily Volume10 Day 441,610
Average Daily Volume3 Month 576,118
Average Volume 576,118
Average Volume10Days 441,610
Beta 1.207
Bid 35.61
Bid Size 1
Board Risk 2
Book Value 7.006
City Cambridge
Compensation As Of Epoch Date 1,767,139,200
Compensation Risk 6
Country United States
Crypto Tradeable 0
Currency USD
Current Price 35.68
Current Ratio 5.034
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 35.86
Day Low 34.355
Debt To Equity 27.321
Display Name Vericel
Earnings Call Timestamp End 1,772,112,600
Earnings Call Timestamp Start 1,772,112,600
Earnings Growth 0.189
Earnings Quarterly Growth 0.173
Earnings Timestamp 1,772,112,600
Earnings Timestamp End 1,778,157,000
Earnings Timestamp Start 1,778,157,000
Ebitda 22,588,000
Ebitda Margins 0.08176
Enterprise To Ebitda 78.388
Enterprise To Revenue 6.409
Enterprise Value 1,770,627,200
Eps Current Year 0.43167
Eps Forward 0.805
Eps Trailing Twelve Months 0.32
Esg Populated 0
Exchange NGM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fax 617 588 5554
Fifty Day Average 34.2598
Fifty Day Average Change 1.4202003
Fifty Day Average Change Percent 0.041453842
Fifty Two Week Change Percent -12.698799
Fifty Two Week High 45.97
Fifty Two Week High Change -10.290001
Fifty Two Week High Change Percent -0.22384165
Fifty Two Week Low 28.95
Fifty Two Week Low Change 6.7299995
Fifty Two Week Low Change Percent 0.23246975
Fifty Two Week Range 28.95 - 45.97
Financial Currency USD
First Trade Date Milliseconds 855,066,600,000
Float Shares 47,579,444
Forward Eps 0.805
Forward P E 44.322983
Free Cashflow 16,049,750
Full Exchange Name NasdaqGM
Full Time Employees 398
Gmt Off Set Milliseconds -14,400,000
Governance Epoch Date 1,775,001,600
Gross Margins 0.74423
Gross Profits 205,599,008
Has Pre Post Market Data 1
Held Percent Insiders 0.014680001
Held Percent Institutions 1.108
Implied Shares Outstanding 50,931,598
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ir Website http://investors.aastrom.com/investors.cfm
Is Earnings Date Estimate 1
Language en-US
Last Fiscal Year End 1,767,139,200
Last Split Date 1,381,881,600
Last Split Factor 1:20
Long Business Summary Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns. Vericel Corporation was formerly known as Aastrom Biosciences, Inc. and changed its name to Vericel Corporation in November 2014. The company was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Long Name Vericel Corporation
Market us_market
Market Cap 1,817,239,552
Market State PREPRE
Max Age 86,400
Message Board Id finmb_24153
Most Recent Quarter 1,767,139,200
Net Income To Common 16,518,000
Next Fiscal Year End 1,798,675,200
Non Diluted Market Cap 1,817,748,732
Number Of Analyst Opinions 7
Open 34.61
Operating Cashflow 51,910,000
Operating Margins 0.24123
Overall Risk 4
Payout Ratio 0.0
Phone 617 588 5555
Post Market Change 0.0
Post Market Change Percent 0.0
Post Market Price 35.68
Post Market Time 1,776,456,605
Previous Close 33.77
Price Eps Current Year 82.65573
Price Hint 2
Price To Book 5.0927777
Price To Sales Trailing12 Months 6.578028
Profit Margins 0.05979
Quick Ratio 4.52
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key strong_buy
Recommendation Mean 1.25
Region US
Regular Market Change 1.91
Regular Market Change Percent 5.65591
Regular Market Day High 35.86
Regular Market Day Low 34.355
Regular Market Day Range 34.355 - 35.86
Regular Market Open 34.61
Regular Market Previous Close 33.77
Regular Market Price 35.68
Regular Market Time 1,776,456,000
Regular Market Volume 424,075
Return On Assets 0.014989999
Return On Equity 0.051090002
Revenue Growth 0.233
Revenue Per Share 5.488
Sand P52 Week Change 0.38150132
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Share Holder Rights Risk 4
Shares Outstanding 50,931,598
Shares Percent Shares Out 0.10569999
Shares Short 5,384,908
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 4,796,343
Short Name Vericel Corporation
Short Percent Of Float 0.1364
Short Ratio 7.61
Source Interval 15
State MA
Symbol VCEL
Target High Price 64.0
Target Low Price 42.0
Target Mean Price 54.57143
Target Median Price 55.0
Total Cash 137,499,008
Total Cash Per Share 2.709
Total Debt 96,891,000
Total Revenue 276,259,008
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps 0.32
Trailing P E 111.5
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 35.92045
Two Hundred Day Average Change -0.240448
Two Hundred Day Average Change Percent -0.006693903
Type Disp Equity
Volume 424,075
Website https://www.vcel.com
Zip 2,139